Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
ORGANIZATION
PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
Major pharma trade organizations issued statements on December 25 following the Japanese government’s decision to push ahead with an “off-year” drug price revision in FY2025, with US and European groups harshly criticizing it as a reversal of pro-innovation policies. The…
To read the full story
Related Article
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
ORGANIZATION
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
- Labor Group Presses Lawmakers to Reflect Rising Costs in Drug Prices
November 26, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…